The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Tevimbra (tislelizumab) for resectable non-small cell lung cancer (NSCLC). It is recommended in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for adult patients at high risk of recurrence. Dr […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!